Norway -
Norwegian -
Statens legemiddelverk
furosemide kalceks 10 mg/ ml
as kalceks - furosemid - injeksjons-/infusjonsvæske, oppløsning - 10 mg/ ml
Norway -
Norwegian -
Statens legemiddelverk
burinex 0.5 mg/ ml
karo pharma ab (1) - bumetanid - injeksjonsvæske, oppløsning - 0.5 mg/ ml
Norway -
Norwegian -
Statens legemiddelverk
burinex 5 mg
karo pharma ab (1) - bumetanid - tablett - 5 mg
Norway -
Norwegian -
Statens legemiddelverk
brintellix 10 mg
farmagon - vortioksetinhydrobromid - tablett, filmdrasjert - 10 mg
Norway -
Norwegian -
Statens legemiddelverk
aclasta 5 mg
abacus medicine a/s - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg
Norway -
Norwegian -
Statens legemiddelverk
aclasta 5 mg
2care4 aps - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg
European Union -
Norwegian -
EMA (European Medicines Agency)
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.